Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

José Rodrigues-Pereira, Joo-Hang Kim, Manuel Magallanes, Dae Ho Lee, Jie Wang, Vinod Ganju, Luis Martínez-Barrera, Helen Barraclough, Maximiliano Van Kooten, Mauro Orlando, None, A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 6, pp. 1907- 1914 ,(2011) , 10.1097/JTO.0B013E318226B5FA

Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer, Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis Journal of Cellular and Molecular Medicine. ,vol. 14, pp. 51- 69 ,(2010) , 10.1111/J.1582-4934.2009.00991.X

Alejandro R. Jadad, R.Andrew Moore, Dawn Carroll, Crispin Jenkinson, D.John M. Reynolds, David J. Gavaghan, Henry J. McQuay, Assessing the quality of reports of randomized clinical trials : is blinding necessary? Controlled Clinical Trials. ,vol. 17, pp. 1- 12 ,(1996) , 10.1016/0197-2456(95)00134-4

Michael S Gordon, David S Mendelson, Mitchell Gross, Martina Uttenreuther-Fischer, Mahmoud Ould-Kaci, Yihua Zhao, Peter Stopfer, David B Agus, None, A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors Investigational New Drugs. ,vol. 31, pp. 409- 416 ,(2013) , 10.1007/S10637-012-9904-9

A E Ades, Mark Sculpher, Alex Sutton, Keith Abrams, Nicola Cooper, Nicky Welton, Guobing Lu, Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis PharmacoEconomics. ,vol. 24, pp. 1- 19 ,(2006) , 10.2165/00019053-200624010-00001

Giulio Metro, Lucio Crinò, The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Review of Anticancer Therapy. ,vol. 11, pp. 673- 682 ,(2011) , 10.1586/ERA.11.34

Mark A. Socinski, Robert N. Raju, Thomas Stinchcombe, Darren M. Kocs, Linda S. Couch, David Barrera, Steven R. Rousey, Janak K. Choksi, Robert Jotte, Debra A. Patt, Phillip O. Periman, Howard R. Schlossberg, Charles H. Weissman, Yunfei Wang, Lina Asmar, Sharon Pritchard, Jane Bromund, Guangbin Peng, Joseph Treat, Coleman K. Obasaju, Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 5, pp. 1963- 1969 ,(2010) , 10.1097/JTO.0B013E3181FD42EB

Neil Hawkins, David A. Scott, Beth S. Woods, Nicholas Thatcher, No Study Left Behind: A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data Value in Health. ,vol. 12, pp. 996- 1003 ,(2009) , 10.1111/J.1524-4733.2009.00541.X

Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954

Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Skaidrius Miliauskas, Alexandru Calin Grigorescu, Carina Hillenbach, Hrefna Kristin Johannsdottir, Barbara Klughammer, Emilio Esteban Gonzalez, Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study Lancet Oncology. ,vol. 13, pp. 300- 308 ,(2012) , 10.1016/S1470-2045(11)70385-0